8-K: Humacyte's ATEV Shows Superior Results in Phase 3 Trial for Hemodialysis Access

Humacyte's acellular tissue engineered vessel (ATEV) demonstrated superior function and patency compared to autogenous fistula in a Phase 3 clinical trial for hemodialysis access, particularly in female, obese, and diabetic patients.

Summary

• Humacyte announced positive results from its Phase 3 clinical trial (V007) of the acellular tissue engineered vessel (ATEV) for arteriovenous (AV) access in patients with end-stage renal disease.
• The ATEV showed superior function and patency at both six and 12 months compared to the current standard of care, autogenous fistula.
• The trial included 242 patients and was a prospective, multi-center, randomized study.
• At six months, 81.3% of patients with ATEV had functional patency compared to 66.4% with AV fistula.
• At 12 months, 68.3% of ATEV patients had secondary patency compared to 62.2% with AV fistula.
• The joint test for superiority of ATEV was statistically significant (p=0.0071).
• Patients receiving ATEV also had a significantly longer duration of hemodialysis over the first 12 months (p=0.0162).
• Subgroup analysis showed ATEV had superior patency and hemodialysis duration in female, obese, and diabetic patients.
• In female patients, ATEV showed significantly higher patency rates (p<0.0001) and longer hemodialysis duration (8.3 months vs 5.0 months, p=0.0011).
• In obese patients, ATEV showed significantly higher patency rates (p=0.0001) and longer hemodialysis duration (7.7 months vs 4.5 months, p=0.0020).
• In diabetic patients, ATEV showed significantly higher patency rates (p=0.0024) and longer hemodialysis duration (7.4 months vs 5.5 months, p=0.0155).
• Infection rates were low in both groups, with 9.1% in ATEV and 9.9% in AV fistula.
• Thrombosis was more frequent in ATEV patients (52.1%) compared to AV fistula (9.1%), but 94% of ATEV thrombosis cases were successfully treated.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results, indicating a significant advancement in hemodialysis access. The superior performance of ATEV, especially in challenging patient subgroups, is a strong positive. However, the higher incidence of thrombosis and the investigational status of the product temper the overall sentiment slightly.

Positives

• The ATEV showed statistically significant superiority over autogenous fistula in the primary endpoints of functional patency at six months and secondary patency at 12 months.
• The ATEV demonstrated superior performance in key subgroups including female, obese, and diabetic patients, who typically have poor outcomes with standard procedures.
• Patients receiving the ATEV experienced a significantly longer duration of hemodialysis access compared to those receiving an AV fistula.
• Infection rates were low and comparable between the ATEV and AV fistula groups.
• The majority of thrombosis events in ATEV patients were successfully treated.

Negatives

• Thrombosis occurred more frequently in patients implanted with the ATEV (52.1%) compared to those treated with AV fistula (9.1%).
• Treatment-Emergent Adverse Events (TAEEs) occurred in a slightly higher percentage of patients implanted with the ATEV (98.3%) compared to those treated with AV fistula (96.7%).

Risks

• The ATEV is still an investigational product and has not been approved for sale by the FDA or any other regulatory agency.
• The higher incidence of thrombosis in the ATEV group, although mostly treatable, could pose a risk.
• The company faces risks related to regulatory approvals, commercialization, and manufacturing at scale.
• There are risks associated with the company's ability to successfully complete preclinical and clinical trials for its ATEVs.

Future Outlook

The company is focused on advancing its ATEV through regulatory approvals and commercialization, with ongoing clinical trials for multiple vascular applications. A Biologics License Application for the ATEV in vascular trauma is currently under review by the FDA.

Management Comments

• Dr. Hussain stated that the availability of the ATEV could be game-changing in improving arteriovenous access for many hemodialysis patients.
• Dr. Hussain was particularly pleased to see positive results in female, obese, and diabetic patients, groups which typically have poor outcomes with autogenous fistula procedures.

Industry Context

This announcement is significant as it addresses a critical need for improved vascular access in hemodialysis patients, particularly in subgroups with historically poor outcomes. The results position Humacyte as a potential leader in the regenerative medicine space for vascular applications.

Comparison to Industry Standards

• The current standard of care for hemodialysis access is the autogenous fistula, which has limitations, especially in certain patient subgroups.
• The ATEV demonstrated superior patency rates compared to autogenous fistula, which is a significant improvement.
• Companies like W. L. Gore & Associates and Medtronic offer synthetic grafts for vascular access, but Humacyte's ATEV is a bioengineered tissue, which may offer advantages in terms of biocompatibility and long-term patency.
• The results of the V007 trial suggest that the ATEV could become a preferred option for hemodialysis access, particularly in patients with challenging anatomies or comorbidities.

Stakeholder Impact

• Shareholders will likely view the positive trial results favorably.
• Patients with end-stage renal disease, particularly those in the female, obese, and diabetic subgroups, stand to benefit from the improved outcomes.
• Healthcare providers may adopt the ATEV as a preferred option for hemodialysis access.
• The company's employees may be positively impacted by the potential for commercial success.

Next Steps

• Humacyte will continue to pursue regulatory approvals for the ATEV.
• The company will continue to advance its ATEV through clinical trials for multiple vascular applications.
• The company will focus on commercialization of the ATEV upon regulatory approval.

Key Dates

Keywords

ATEV, Arteriovenous Access, Hemodialysis, End-Stage Renal Disease, Clinical Trial, Vascular Access, Autogenous Fistula, Patency, Biotechnology, Regenerative Medicine